Multicellular immunosuppressive networks in microsatellite-stable colorectal cancer: CD8+ T cell exclusion, dysfunction, exhaustion, and therapeutic implications
Open Access
- 25 August 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1945393
Abstract
Microsatellite-stable (MSS) colorectal cancer (CRC), comprising ~85–90% of cases, remains almost universally refractory to PD-1/PD-L1 monotherapy (objective response rate 5–10%), in stark contrast to the marked efficacy of immune checkpoint inhibitors (ICIs) in microsatellite-instability-high (MSI-H) disease. Here we synthesize evidence that CD8 + T cell exclusion, dysfunction, and exhaustion in MSS CRC are orchestrated not by cell-autonomous failures but by a multicellular immunosuppressive network in which tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs) cooperate through mechanistically distinct yet spatially integrated axes. We propose a four-layer hierarchical model (physical exclusion, effector dysfunction, metabolic deprivation, and active suppression) that culminates in a stereotyped three-layer spatial niche best documented in CRC liver metastases (outer mCAF belt, Tex/TSTR band, inner SPP1 + TAM aggregates). MSS-associated mechanisms include the TAM-derived COX2/PGE2/TIGIT axis driving terminal exhaustion, a functional IL-10 - /IL-10 + Treg dichotomy, and CAF-mediated suppression of dendritic-cell CXCL9/10 production that blocks CXCR3 + CD8 recruitment. Effective therapeutic strategies must therefore target multiple layers simultaneously, including TAM reprogramming, stromal remodeling, precision Treg depletion, and MDSC differentiation, rather than relying on additional checkpoint inhibitors, which have proven insufficient as monotherapy or in dual combinations.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 84 references indexed in Scilit:
- Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunityMolecular Oncology, 2026
- Increased CD103−CD8+ TILs with TPEX phenotype replenish anti-tumor T cell pool in mismatch repair-proficient CRCCancer Immunology, Immunotherapy, 2025
- IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarizationCancer Immunology, Immunotherapy, 2025
- Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancerCancer Cell, 2024
- CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasisCancer Cell, 2024
- Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident TregsCancer Immunology, Immunotherapy, 2024
- Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancerCancer Cell, 2024
- Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancerCancer Immunology, Immunotherapy, 2022
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal CancerCancer Cell, 2019